| 1. |
Ninin E, Milpied N, Moreau P, et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants.
Clin Infect Dis 2001;33:41-7.
|
| 2. |
Ferrara JL, Deeg HJ. Graft-versus-host disease.
N Engl J Med 1991;324:667-74.
|
| 3. |
Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation.
Immunol Rev 1997;157:73-8.
|
| 4. |
Lenarsky C. Mechanisms in immune recovery after bone marrow transplantation. Management of posttransplant immune deficiency.
Am J Pediatr Hematol Oncol 1993;15:49-55.
|
| 5. |
Atkinson K. Reconstruction of the haemopoietic
and immune systems after marrow transplantation.
Bone Marrow Transplant 1990;5:209-26.
|
| 6. |
Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program.
Blood 2000;96:4096-102.
|
| 7. |
Zimmerli W, Zarth A, Gratwohl A, et al. Neutrophil function and pyogenic infections in bone marrow transplant recipients.
Blood 1991;77:393-9.
|
| 8. |
Clark RA, Johnson FL, Klebanoff SJ, et al. Defective neutrophil chemotaxis in bone marrow transplant patients.
J Clin Invest 1976;58:22-31.
|
| 9. |
Woo SB, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients.
Cancer 1993;72:1612-7.
|
| 10. |
Wald A, Leisenring W, van Burik JA, et al. Epidemiology ofAspergillus infections in a large cohort of patients undergoing bone marrow transplantation.
J Infect Dis 1997;175:1459-66.
|
| 11. |
Bushelman SJ, Callen JP, Roth DN, et al. DisseminatedFusarium solani infection.
J Am Acad Dermatol 1995;32:346-51.
|
| 12. |
Krcmery V, Mateicka F, Kunova A, et al. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazole.
Support Care Cancer 1999;7:39-43.
|
| 13. |
Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes.
Eur J Haematol 1999;63:77-85.
|
| 14. |
Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).
Clin Infect Dis 1999;28:1071-9.
|
| 15. |
Bow EJ, Loewen R, Cheang MS, et al. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia:
the pathogenetic role of the antileukemic regimen.
Clin Infect Dis 1995;21:361-9.
|
| 16. |
Bow EJ, Loewen R, Cheang MS, et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults.
J Clin Oncol 1997;15:2254-61.
|
| 17. |
Wingard JR, Dick JD, Merz WG, et al. Differences in virulence of clinical isolates ofCandida tropicalis andCandida albicans in mice.
Infect Immun 1982;37:833-6.
|
| 18. |
Guiot HF, Fibbe WE, van't Wout JW. Risk
factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis.
Clin Infect Dis 1994;18:525-32.
|
| 19. |
O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients.
J Clin Oncol 1994;12:827-34.
|
| 20. |
Marr KA, Seidel K, White TC, et al. Candidemia
in allogeneic blood and marrow transplant
recipients: evolution of risk factors after the adoption of prophylactic fluconazole.
J Infect Dis 2000;181:309-16.
|
| 21. |
Tollemar J, Ringden O, Bostrom L, et al. Variables predicting deep fungal infections in bone marrow transplant recipients.
Bone Marrow Transplant 1989;4:635-41.
|
| 22. |
Walsh TJ, Hiemenz J, Pizzo PA. Editorial Response: Evolving risk factors for invasive fungal infections – all neutropenic patients are not the same.
Clin Infect Dis 1994;18:793-8.
|
| 23. |
Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation.
J Infect Dis 1991;164:731-40.
|
| 24. |
Sable CA, Donowitz GR. Infections in bone marrow transplant recipients.
Clin Infect Dis 1994;18:273-81.
|
| 25. |
Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem-cell transplants: an international consensus.
Clin Infect Dis 2002;34:7-14.
|
| 26. |
Kontoyiannis DP, Luna MA, Samuels BI, et al. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis.
Infect Dis Clin North Am 2000;14:721-39.
|
| 27. |
Bolognia JL, Braverman IM. Skin manifestations of internal disease. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds.
Harrison's Principles of Internal Medicine. 14 ed. New York: McGraw-Hill; 1998:310-28.
|
| 28. |
Allo MD, Miller J, Townsend T, et al. Primary cutaneous aspergillosis associated with Hickman intravenous catheters.
N Engl J Med 1987;317:1105-8.
|
| 29. |
Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused byAspergillus .
Clin Infect Dis 2000;30:696-709.
|
| 30. |
Walsh TJ. Editorial Response: Primary cutaneous aspergillosis – an emerging infection among immunocompromised patients.
Clin Infect Dis 1998;27:453-7.
|
| 31. |
Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.
Blood 1997;90:999-1008.
|
| 32. |
Mirza N, Lanza DC. Diagnosis and management of rhinosinusitis before scheduled immunosuppression: a schematic approach to the prevention of acute fungal rhinosinusitis.
tolaryngol Clin North Am 2000;33:313-21.
|
| 33. |
Sallah S. Hepatosplenic candidiasis in patients with acute leukemia: increasingly encountered complication.
Anticancer Res 1999;19:757-60.
|
| 34. |
Worthy SA, Flint JD, Muller NL. Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings.
Radiographics 1997;17:1359-71.
|
| 35. |
Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis.
Radiology 1985;157:611-4.
|
| 36. |
von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival.
Respiration 1995;62:341-7.
|
| 37. |
Choi YH, Leung AN. Radiologic findings: pulmonary infections after bone marrow transplantation.
J Thorac Imaging 1999;14:201-6.
|
| 38. |
Libshitz HI, Pagani JJ. Aspergillosis and mucormycosis: two types of opportunistic fungal pneumonia.
Radiology 1981;140:301-6.
|
| 39. |
Kami M, Tanaka Y, Kanda Y, et al. Computed tomographic scan of the chest, latex agglutination test and plasma beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients.
Haematologica 2000;85:745-52.
|
| 40. |
Ho PL, Yuen KY. Aspergillosis in bone marrow transplant recipients.
Crit Rev Oncol Hematol 2000;34:55-69.
|
| 41. |
Miaux Y, Ribaud P, Williams M, et al. MR of cerebral aspergillosis in patients who have had bone marrow transplantation.
Am J Neuroradiol 1995;16:555-62.
|
| 42. |
Wingard JR. Fungal infections after bone marrow transplant.
Biol Blood Marrow Transplant 1999;5:55-68.
|
| 43. |
Hagensee ME, Bauwens JE, Kjos B, et al.
Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992.
Clin Infect Dis 1994;19:402-8.
|
| 44. |
Sugar AM. Mucormycosis.
Clin Infect Dis 1992;14:S126-9.
|
| 45. |
Samuels BI, Pagani JJ, Libshitz HI. Radiologic features of Candida infections. In: Bodey GP, ed.
Candidiasis: Pathogenesis, Diagnosis and Treatment . New York: Raven Press; 1993:137-56.
|
| 46. |
Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis.
Am J Med 1996;100:171-8.
|
| 47. |
Glazer M, Nusair S, Breuer R, et al. The role of BAL in the diagnosis of pulmonary mucormycosis.
Chest 2000;117:279-82.
|
| 48. |
Jantunen E, Piilonen A, Volin L, et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients.
Bone Marrow Transplant 2000;25:867-71.
|
| 49. |
Nucci M, Biasoli I, Barreiros G, et al. Predictive value of a positive nasal swab for Aspergillus sp. in the diagnosis of invasive aspergillosis in adult neutropenic cancer patients.
Diagn Microbiol Infect Dis 1999;35:193-6.
|
| 50. |
Mitsutake K, Miyazaki T, Tashiro T, et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia.
J Clin Microbiol 1996;34:1918-21.
|
| 51. |
Walsh TJ, Merz WG, Lee JW, et al. Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol.
Am J Med 1995;99:164-72.
|
| 52. |
Morace G, Pagano L, Sanguinetti M, et al. PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies.
J Clin Microbiol 1999;37:1871-5.
|
| 53. |
Stevens DA. Combination immunotherapy and antifungal chemotherapy.
Clin Infect Dis 1998;26:1266-9.
|
| 54. |
Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem-cell transplantation recipients: a prospective validation.
Blood 2001;97:1604-10.
|
| 55. |
Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes.
J Clin Microbiol 1997;35:1353-60.
|
| 56. |
Bretagne S, Costa JM, Marmorat-Khuong A, et al. Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR.
J Clin Microbiol 1995;33:1164-8.
|
| 57. |
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation.
MMWR 2000;49:1-125.
|
| 58. |
Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem-cell transplant recipients.
Clin Infect Dis 2001;33:139-44.
|
| 59. |
Weems JJ, Davis BJ, Tablan OC, et al. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy.
Infect Control 1987;8:71-5.
|
| 60. |
Krasinski K, Holzman RS, Hanna B, et al. Nosocomial fungal infection during hospital renovation.
Infect Control 1985;6:278-82.
|
| 61. |
Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.
Clin Infect Dis 1999;29:253-8.
|
| 62. |
Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne.
Clin Infect Dis 2001;33:1546-8.
|
| 63. |
Bouakline A, Lacroix C, Roux N, et al. Fungal contamination of food in hematology units.
J Clin Microbiol 2000;38:4272-3.
|
| 64. |
Meunier F. Prevention and mycoses in immunocompromised patients.
Rev Infect Dis 1987;9:408-16.
|
| 65. |
Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study.
J Infect Dis 1995;171:1545-52.
|
| 66. |
Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.
N Engl J Med 1992;326:845-51.
|
| 67. |
Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial.
Blood 2000;96:2055-61.
|
| 68. |
Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy.
Clin Infect Dis 1999;28:331-40.
|
| 69. |
Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.
J Infect Dis 1995;172:1035-41.
|
| 70. |
Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.
Ann Intern Med 1993;118:495-503.
|
| 71. |
Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients.
Eur J Clin Microbiol Infect Dis 1994;13:3-11.
|
| 72. |
Ninane J, for the Multicentre Study Group.
A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies.
Eur J Clin Microbiol Infect Dis 1994;13:330-7.
|
| 73. |
Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program.
Ann Intern Med 1994;120:913-8.
|
| 74. |
Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study.
Leuk Lymphoma 1993;11:353-8.
|
| 75. |
Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.
Clin Infect Dis 2000;30:300-5.
|
| 76. |
Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia.
Leukemia 1998;12:1338-43.
|
| 77. |
Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients.
J Antimicrob Chemother 1994;34:247-52.
|
| 78. |
Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.
J Antimicrob Chemother 1995;36:657-63.
|
| 79. |
Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial.
Clin Infect Dis 1999;28:250-5.
|
| 80. |
Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.
Antimicrob Agents Chemother 2000;44:1887-93.
|
| 81. |
Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
Br J Haematol 1999;105:901-11.
|
| 82. |
Meunier-Carpentier F, Snoeck R, Gerain J, et al. Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia.
N Engl J Med 1984;311:1056.
|
| 83. |
Jeffery GM, Beard ME, Ikram RB, et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients.
Am J Med 1991;90:685-92.
|
| 84. |
Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.
Blood 1999;93:3654-61.
|
| 85. |
Rousey SR, Russler S, Gottlieb M, et al. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation.
Am J Med 1991;91:484-92.
|
| 86. |
Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.
J Infect Dis 1992;165:891-7.
|
| 87. |
Tollemar J, Ringden O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Bone Marrow Transplant 1993;12:577-82.
|
| 88. |
Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Bone Marrow Transplant 1999;23:163-8.
|
| 89. |
Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Bone Marrow Transplant 2000;25:853-9.
|
| 90. |
Bodey GP, Anaissie EJ, Elting LS, et al. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B.
Cancer 1994;73:2099-106.
|
| 91. |
Cordonnier C, Beaune J, Offner F, et al. Aspergillosis prior to bone marrow transplantation. Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group.
Bone Marrow Transplant 1995;16:323-4.
|
| 92. |
Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
N Engl J Med 1991;325:1274-7.
|
| 93. |
Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.
Antimicrob Agents Chemother 1993;37:1847-9.
|
| 94. |
Wingard JR, Elfenbein GJ. Host immunologic augmentation for the control of infection.
Infect Dis Clin North Am 1996;10:345-64.
|
| 95. |
Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.
Clin Infect Dis 1997;25:551-73.
|
| 96. |
van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.
Medicine (Baltimore) 1998;77:246-54.
|
| 97. |
Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey.
Eur J Clin Microbiol Infect Dis 1992;11:99-109.
|
| 98. |
Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient.
Oncology 2001;15:351-63.
|
| 99. |
Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group.
Am J Med 1989;86:668-72.
|
| 100. |
Aisner J, Wiernik PH, Schimpff SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response.
Ann Intern Med 1977;86:539-43.
|
| 101. |
Burch PA, Karp JE, Merz WG, et al. Favorable outcome of invasive aspergillosis in patients with acute leukemia.
J Clin Oncol 1987;5:1985-93.
|
| 102. |
Kuhlman JE, Fishman EK, Burch PA, et al. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management.
Chest 1987;92:95-9.
|
| 103. |
Fisher BD, Armstrong D, Yu B, et al. Invasive aspergillosis. Progress in early diagnosis and treatment.
Am J Med 1981;71:571-7.
|
| 104. |
Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis.
Clin Infect Dis 2000;30:662-78.
|
| 105. |
Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
Clin Infect Dis 1999;29:1402-7.
|
| 106. |
Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
N Engl J Med 1999;340:764-71.
|
| 107. |
White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.
Clin Infect Dis 1998;27:296-302.
|
| 108. |
Wingard JR, White MH, Anaissie E, et al.
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia.
Clin Infect Dis 2000;31:1155-63.
|
| 109. |
Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities.
Clin Infect Dis 1998;27:603-18.
|
| 110. |
Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.
Eur J Cancer 1996;32A:814-20.
|
| 111. |
Malik IA, Moid I, Aziz Z, et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia.
Am J Med 1998;105:478-83.
|
| 112. |
Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Am J Med 2000;108:282-9.
|
| 113. |
Ellis ME, Halim MA, Spence D, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever – preliminary observations from a pilot, exploratory study.
J Infect 1995;30:141-6.
|
| 114. |
Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Ann Intern Med 2001;135:412-22.
|
| 115. |
Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.
Rev Infect Dis 1990;12:1147-201.
|
| 116. |
Andriole VT. The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents.
J Antimicrob Chemother 1999;44:151-62.
|
| 117. |
Edwards JE, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections.
Clin Infect Dis 1997;25:43-59.
|
| 118. |
Haron E, Feld R, Tuffnell P, et al. Hepatic candidiasis: an increasing problem in immunocompromised patients.
Am J Med 1987;83:17-26. 2000;31:1155-63.
|
| 119. |
Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia.
N Engl J Med 1994;331:1325-30.
|
| 120. |
Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
Arch Intern Med 1995;155:1093-8.
|
| 121. |
Noskin GA, Pietrelli L, Coffey G, et al. Amphotericin B colloidal dispersion for treatment
of candidemia in immunocompromised patients.
Clin Infect Dis 1998;26:461-7.
|
| 122. |
Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
Bone Marrow Transplant 1997;20:39-43.
|
| 123. |
Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Clin Infect Dis 1998;26:1383-96.
|
| 124. |
Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
Pediatr Infect Dis J
1999;18:702-8.
|
| 125. |
Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Bone Marrow Transplant 1997;19:343-7.
|
| 126. |
Anaissie E, White M, Uzun O, et al. Amphotericin B lipid complex vs amphotericin B for the treatment of invasive candidiasis: a prospective randomized multicenter trial. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract LM21]. San Francisco, 1995.
|
| 127. |
Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis.
N Engl J Med 2002;347:2020-9.
|
| 128. |
Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes.
Clin Infect Dis 1992;14:875-83.
|
| 129. |
Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.
Clin Infect Dis 1995;21:994-6.
|
| 130. |
Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
J Clin Microbiol 1998;36:2950-6.
|
| 131. |
Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis – a contraindication to marrow transplantation?
Blood 1994;84:2811-4.
|
| 132. |
Andstrom EE, Ringden O, Remberger M, et al. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients.
Mycoses 1996;39:185-93.
|
| 133. |
Ringden O, Andstrom E, Remberger M, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin.
Bone Marrow Transplant 1994;14 Suppl 5:S10-4.
|
| 134. |
White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
Clin Infect Dis 1997;24:635-42.
|
| 135. |
Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.
Br J Haematol 1998;103:205-12.
|
| 136. |
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med 2002;347:408-15.
|
| 137. |
Maertens J, Raad I, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and
efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, lipid amphotericin B, or azoles.Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract 1103]. Toronto, Canada, 2000.
|
| 138. |
McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience.
Clin Infect Dis 1993;17:397-404.
|
| 139. |
Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis.
Am J Med 1994;97:135-44.
|
| 140. |
Stevens DA, Lee JY. Analysis of compassionate
use itraconazole therapy for invasive aspergillosis
by the NIAID Mycoses Study Group criteria.
Arch Intern Med 1997;157:1857-62.
|
| 141. |
Richard C, Romon I, Baro J, et al. Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome.
Bone Marrow Transplant 1993;12:237-41.
|
| 142. |
Offner F, Cordonnier C, Ljungman P, et al.
Impact of previous aspergillosis on the outcome
of bone marrow transplantation.
Clin Infect Dis 1998;26:1098-103.
|
| 143. |
Karp JE, Burch PA, Merz WG. An approach
to intensive antileukemia therapy in patients
with previous invasive aspergillosis.
Am J Med 1988;85:203-6.
|
